Baseline characteristics of patients
| Amlodipine group (n=49) | Control group (n=49) | p Value | |
|---|---|---|---|
| Age in years (mean±SD) | 69±10 | 69±12 | 0.87 |
| Male sex, n (%) | 31 (%) | 26 (%) | 0.31 |
| Risk factors/history, n (%) | |||
| Smoking | 2 (4%) | 3 (4%) | 0.64 |
| Diabetes mellitus | 22 (44%) | 27 (55%) | 0.23 |
| Hypertension | 48 (98%) | 46 (94%) | 0.31 |
| Previous myocardial infarction* | 21 (43%) | 26 (53%) | 0.31 |
| ACS within 1 month† | 22 (45%) | 15 (30%) | 0.15 |
| Concomitant medications, n (%) | |||
| Pantoprazole | 30 (61%) | 27 (55%) | 0.53 |
| ACE inhibitor | 33 (67%) | 34 (69%) | 0.83 |
| Angiotensin receptor blocker | 10 (20%) | 8 (16%) | 0.60 |
| β-blocker | 34 (69%) | 35 (71%) | 0.82 |
| Spironolactone | 4 (8%) | 4 (8%) | 1.00 |
| α-blocker | 2 (4%) | 6 (12%) | 0.14 |
| Digoxin | 0 (0%) | 3 (6%) | 0.08 |
| Heparin‡ | 5 (10%) | 8 (16%) | 0.37 |
| Cytochrome P450 3A4 metabolising statin§ | 45 (92%) | 44 (90%) | 0.72 |
| Serotonin-selective inhibitor | 0 (0%) | 0 (0%) | 1.00 |
| Amiodarone | 0 (0%) | 0 (0%) | 1.00 |
| Ginkgo biloba (herb) | 0 (0%) | 0 (0%) | 1.00 |
| Laboratory data (mean±SD) | |||
| Hb, g/dl | 13±1.8 | 13±2.0 | 0.31 |
| Platelets, 109/l | 213±55 | 208±54 | 0.69 |
| Creatinine, μmol/l | 100±29 | 98±29 | 0.74 |
| Bilirubin, μmol/l | 9±3.7 | 11±6.0 | 0.18 |
| Baseline platelet reactivity at day 0 (mean±SD) | |||
| P2Y12 reactivity unit | 206±82 | 213±91 | 0.72 |
| Platelet inhibition, % | 38±23 | 37±21 | 0.78 |
*Any history of myocardial infarction, defined as elevated troponin with either ischaemic chest pain or ECG change.
†Acute coronary syndrome defined as Unstable angina, non-ST elevation or ST-elevation myocardial infarction within 1 month before enrolment.
‡Heparin used between 7 and 2 days before enrolment.
§Only simvastatin or atorvastatin used.